Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Humacyte, Inc. HUMA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.50
+511.3%

Humacyte, Inc. (HUMA) is a Biotechnology company in the Healthcare sector, currently trading at $0.74. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is HUMA = $5 (+511.3% upside).

Valuation: HUMA trades at a trailing Price-to-Earnings (P/E) of -2.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.05.

Financials: revenue is $2M, -100%/yr average growth. Net income is $41M (loss), growing at -78.1%/yr. Net profit margin is -2003.6% (negative). Gross margin is -736.5% (-309 pp trend).

Balance sheet: total debt is $65M against $3M equity (Debt-to-Equity (D/E) ratio 20.86, leveraged). Current ratio is 3.69 (strong liquidity). Debt-to-assets is 55.7%. Total assets: $116M.

Analyst outlook: 10 / 11 analysts rate HUMA as buy (91%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 33/100 (Fail), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

$4.50
▲ 511.33% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Humacyte, Inc., the average price target is $4.50, with a high forecast of $6.00, and a low forecast of $3.00.
Highest Price Target
$6.00
Average Price Target
$4.50
Lowest Price Target
$3.00

HUMA SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HUMA

✓
VALUE Pass
100/100
HUMA trades at a trailing Price-to-Earnings (P/E) of -2.5 (S&P 500 average ~25). Forward PEG 0.05 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $5, implying +579.3% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
HUMA: -100%/yr revenue is, -78.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
HUMA: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
33/100
Balance sheet HUMA: Debt-to-Equity (D/E) ratio 20.86 (leveraged), Current ratio is 3.69 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
100/100
Analyst outlook: 10 / 11 analysts rate HUMA as buy (91%). Analyst consensus target is $5 (+579.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HUMA: Net profit margin is -2003.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.547-2.93
Volume4.39M
Avg Volume (30D)6.97M
Market Cap$115.4M
Beta (1Y)2.11
Share Statistics
EPS (TTM)-0.26
Shares Outstanding$158.16M
IPO Date2020-12-01
Employees218
CEOLaura E. Niklason
Financial Highlights & Ratios
Revenue (TTM)$2.04M
Gross Profit$-15.01M
EBITDA$-100.09M
Net Income$-40.83M
Operating Income$-107.44M
Total Cash$50.5M
Total Debt$64.85M
Net Debt$14.35M
Total Assets$116.37M
Price / Earnings (P/E)-2.8
Price / Sales (P/S)56.62
Analyst Forecast
1Y Price Target$4.50
Target High$6.00
Target Low$3.00
Upside+511.3%
Rating ConsensusBuy
Analysts Covering11
Buy 91% Hold 9% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS44486Q1031

Price Chart

Track all markets on TradingView
HUMA
Humacyte, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.55 52WK RANGE 2.93

People Also View

CYTK
CYTK
Cytokinetics, Incorporated
$65.37
-1.48%
 MIRM
MIRM
Mirum Pharmaceuticals, Inc.
$96.40
-0.52%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.77
+0.05%
 GPCR
GPCR
Structure Therapeutics Inc.
$54.25
+1.94%
 IMCR
IMCR
Immunocore Holdings plc
$31.64
-0.16%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.97
+4.11%
 VRDN
VRDN
Viridian Therapeutics, Inc.
$14.88
-2.04%
 KALV
KALV
KalVista Pharmaceuticals, Inc.
$20.86
+2.81%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message